Surrozen (NASDAQ:SRZN) Major Shareholder Tcg Crossover Gp Ii, Llc Buys 12,374 Shares

Surrozen, Inc. (NASDAQ:SRZN) major shareholder Tcg Crossover Gp Ii, Llc purchased 12,374 shares of the firm’s stock in a transaction on Thursday, March 12th. The stock was acquired at an average price of $24.99 per share, with a total value of $309,226.26. Following the completion of the transaction, the insider owned 657,301 shares in the company, valued at approximately $16,425,951.99. This trade represents a 1.92% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Tcg Crossover Gp Ii, Llc also recently made the following trade(s):

• On Monday, March 16th, Tcg Crossover Gp Ii, Llc bought 1,190 shares of Surrozen stock. The shares were bought at an average cost of $24.99 per share, with a total value of $29,738.10.
• On Friday, March 13th, Tcg Crossover Gp Ii, Llc acquired 35,433 shares of Surrozen stock. The stock was bought at an average cost of $24.88 per share, for a total transaction of $881,573.04.
• On Thursday, February 12th, Tcg Crossover Gp Ii, Llc purchased 1,093 shares of Surrozen stock. The stock was purchased at an average price of $23.86 per share, for a total transaction of $26,078.98.
• On Wednesday, February 11th, Tcg Crossover Gp Ii, Llc purchased 17,763 shares of Surrozen stock. The shares were acquired at an average price of $23.57 per share, with a total value of $418,673.91.
• On Tuesday, February 3rd, Tcg Crossover Gp Ii, Llc bought 4,355 shares of Surrozen stock. The stock was acquired at an average price of $21.94 per share, with a total value of $95,548.70.
• On Monday, February 2nd, Tcg Crossover Gp Ii, Llc acquired 731 shares of Surrozen stock. The stock was bought at an average price of $21.38 per share, with a total value of $15,628.78.
• On Friday, January 30th, Tcg Crossover Gp Ii, Llc bought 4,271 shares of Surrozen stock. The stock was purchased at an average price of $21.39 per share, with a total value of $91,356.69.

Surrozen Stock Performance

Shares of NASDAQ SRZN traded up $0.29 during midday trading on Monday, hitting $25.50. 33,763 shares of the stock traded hands, compared to its average volume of 112,361. The business has a 50 day moving average price of $23.46 and a two-hundred day moving average price of $18.20. Surrozen, Inc. has a one year low of $5.90 and a one year high of $29.59. The company has a market cap of $218.56 million, a PE ratio of -1.14 and a beta of 0.53.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. China Universal Asset Management Co. Ltd. increased its position in shares of Surrozen by 50.0% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 1,500 shares of the company’s stock valued at $34,000 after buying an additional 500 shares during the period. Persistent Asset Partners Ltd bought a new position in shares of Surrozen in the fourth quarter valued at approximately $99,000. Citadel Advisors LLC grew its stake in Surrozen by 32.8% during the third quarter. Citadel Advisors LLC now owns 13,875 shares of the company’s stock valued at $179,000 after acquiring an additional 3,424 shares in the last quarter. Marshall Wace LLP purchased a new position in Surrozen during the fourth quarter valued at approximately $247,000. Finally, Geode Capital Management LLC increased its holdings in Surrozen by 22.6% during the 2nd quarter. Geode Capital Management LLC now owns 30,963 shares of the company’s stock worth $277,000 after acquiring an additional 5,702 shares during the period. Hedge funds and other institutional investors own 66.57% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on SRZN. Wall Street Zen upgraded Surrozen to a “sell” rating in a research note on Friday, November 28th. Cantor Fitzgerald assumed coverage on shares of Surrozen in a research report on Thursday, February 19th. They issued an “overweight” rating and a $40.00 price objective on the stock. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Surrozen in a research report on Thursday, January 22nd. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $36.00.

Surrozen Company Profile

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.